Patients with tumors that did not express thymidylate synthase responded to chemotherapy. Inhibition of thymidylate synthase is one of the main mechanisms of action of 5-FU and previous findings ...

The FDA highlights increased toxicity risks in patients with DPD deficiency when using Xeloda and 5-FU, urging genetic testing before treatment. DPD deficiency leads to severe side effects from ...

have developed an animal model of chemotherapy-induced damage to the CNS and have demonstrated that systemic treatment with a single chemotherapeutic agent, 5-fluoruracil (5-FU), is sufficient to ...

This process helps prevent the patient from developing toxic or fatal side effects from this chemo. But ... exposure to 5-FU is often fatal. If a patient develops toxicity to 5-FU or capecitabine ...